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Background: Optimal treatment of acute ST-elevation myocardial infarction (STEMI) involves rapid diagnosis, and
transfer to a cardiac centre capable of percutaneous coronary intervention (PCI) for immediate mechanical
revascularisation. Successful treatment requires rapid return of perfusion to the myocardium achieved by
thromboaspiration, passivation of the culprit lesion with stent scaffolding and systemic inhibition of thrombosis and
platelet activation. A delicate balance exists between thrombosis and bleeding and consequently anti-thrombotic
and antiplatelet treatment regimens continue to evolve. The desire to achieve reperfusion as soon as possible, in
the setting of high platelet reactivity, requires potent and fast-acting anti-thrombotic/anti-platelet therapies. The
associated bleeding risk may be minimised by use of short-acting anti-thrombotic intravenous agents. However,
effective oral platelet inhibition is required to prevent recurrent thrombosis. The interaction between baseline
platelet reactivity, timing of revascularisation and effective inhibition of thrombosis is yet to be formally
investigated.
Methods/Design: We present a protocol for a prospective observational study in patients presenting with acute
STEMI treated with primary PCI (PPCI) and receiving bolus/infusion bivalirudin and prasugrel therapy. The objective
of this study is to describe variation in platelet reactivity, as measured by the multiplate platelet function analyser,
at presentation, the end of the PPCI procedure and 1, 2, & 24 hours post-procedure. We intend to assess the
prevalence of high residual platelet reactivity within 24 hours of PPCI in acute STEMI patients receiving prasugrel
and bivalirudin. Additionally, we will investigate the association between high platelet reactivity before and after
PPCI and the door-to-procedure completion time.
This is a single centre study with a target sample size of 108 participants.
Discussion: The baseline platelet reactivity on presentation with a STEMI may impact on the effect of acute
anti-thrombotic and anti-platelet therapy and expose patients to a heightened risk of bleeding or ongoing
thrombosis. This study will define the baseline variation in platelet reactivity in a population of patients experiencing
acute STEMI and assess the pharmacodynamic response to combined treatment with bivalirudin and prasugrel. The
data obtained from this trial will be hypothesis generating for future trials testing alternative pharmacotherapies in
the acute phase of treatment for STEMI.
Trial registration: This study has approval from Wiltshire research ethics committee (10/H0106/87) and is
registered with current controlled trials (www.controlled-trials.com/ISRCTN82257414).
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Primary percutaneous coronary intervention (PPCI) is
accepted as the optimal treatment for acute ST-elevation
myocardial infarction (STEMI) [1]. Restoration of myo-
cardial perfusion is achieved by thrombo-aspiration, pas-
sivation of the culprit lesion with stent scaffolding and
systemic inhibition of thrombosis and platelet activation.
Platelet activation occurs early on in a cascade of
events leading to coronary arterial occlusion and STEMI.
Therefore, anti-platelet therapy is fundamental to the
successful re-canalisation and subsequent reperfusion of
the myocardium. The nature of STEMI treatment is
time critical and currently anti-thrombotic treatment in-
volves using both oral and intravenous agents to confer
immediate and long-term anti-thrombotic effects. Sig-
nificant advances in the inhibition of platelet activity
have occurred in recent years and current data supports
the use of increasingly potent anti-thrombotic agents
and platelet inhibitors to limit the risk of future cardiac
events, including mortality. However, increasingly potent
and advanced pharmacotherapy comes at a financial cost
and with an increased risk of complications, particularly
bleeding. A balance has to be achieved between effective
suppression of thrombosis, prevention of significant bleed-
ing and cost.
The Bristol Heart Institute (BHI) anti-thrombotic proto-
col for the treatment of STEMI was revised in 2010. The
revision implemented conversion from using un-
fractionated heparin (UFH) with glycoprotein 2b/3a re-
ceptor inhibitors (GPI) to using bivalirudin monotherapy
(a drug with rapid onset/offset and excellent bleeding pro-
file) in the catheter laboratory and, additionally, conver-
sion from clopidogrel to prasugrel (a drug with a
consistent and potent platelet inhibitory effect) there-
after. Prasugrel is administered to patients on arrival at
the BHI prior to undertaking angiography and PPCI.
Use of bivalirudin has been shown to offer equivalent
benefit in terms of limiting major adverse cardiac events
(MACE), with a reduction in cardiac mortality and
bleeding versus UFH plus GPI [2]. Prasugrel is a potent
inhibitor of the platelet ADP receptor P2Y12. It was
tested against clopidogrel in the TRITON-TIMI 38 trial
and demonstrated a significant reduction in a composite
outcome of cardiac mortality, non-fatal myocardial infarc-
tion and non-fatal stroke in the treatment of STEMI [3].
The use of prasugrel and bivalirudin in the acute treat-
ment of STEMI offers excellent anti-platelet and anti-
thrombotic effect [2,3]. The combination of prasugrel
with bivalirudin should confer increased protection
against early thrombotic events, as prasugrel has been
demonstrated to offer faster inhibition of platelet re-
activity compared to clopidogrel [4]. However, it should
be noted that the HORIZONS-AMI trial revealed an in-
creased rate of very early stent thrombosis at 24 hourswith bivalirudin monotherapy. Reassuringly, at 30 days
the stent thrombosis rate was not statistically different
in both treatment groups [5]. This transient early nega-
tive outcome with bivalirudin most likely relates to the
pharmacokinetics of the drug, and the protocol of ad-
ministration. Bivalirudin is administered intravenously,
with an initial bolus (0.75 mg/kg) and then an infusion
(1.75 mg/kg/h) until the completion of the angiography/
PCI procedure. Bivalirudin has a half-life of ≈ 25 minutes
and, therefore, thrombin activity is restored fairly rapidly
when the infusion stops. The increase in acute stent
thrombosis may signal a gap in anti-thrombotic protection
arising from a gap between the waning anti-thrombin ef-
fect of Bivalirudin and the onset of platelet inhibition from
clopidogrel. Prasugrel has been demonstrated to achieve
effective platelet inhibition (>40% inhibition of platelet ac-
tivity) within 30 minutes of oral ingestion in patients with
stable angina, compared with 2 hours for equivalent inhib-
ition with clopidogrel [4]. Despite impressive pharmacody-
namic data in a stable population, recent studies of
patients presenting with STEMI, treated with prasugrel,
demonstrate a delayed inhibition of platelet function, ex-
tending beyond 2 hours [6,7].
The 2010 revision of the BHI anti-thrombotic protocol
(preceding data relating to delayed prasugrel effect in
STEMI) assumes that combined prasugrel and bivaliru-
din therapy for the treatment of STEMI will provide ef-
fective anti-platelet and anti-thrombotic inhibition,
minimising the risk of acute stent thrombosis and bleed-
ing. The validation of this assumption in ‘real-world’
STEMI patients has not yet been tested.
Aim
We hypothesise that continued reductions in the “door to
balloon” time (time from hospital admission to achieving
an open artery in the catheter laboratory) may result in
some patients undergoing PPCI with incomplete P2Y12
blockade, leading to an increase in the risk of early throm-
botic events. We speculate that the rapid restoration of
coronary flow achieved with PPCI may offer inadequate
time to achieve platelet inhibition with prasugrel, prior to
the loss of the anti-thrombin effect of bivalirudin.
Therefore, the objectives of this study are to describe
the prevalence of high residual platelet reactivity within
24 hours of PPCI in acute STEMI patients receiving a
prasugrel/bivalirudin anti-platelet regime and, to assess
the association between high residual platelet reactivity
after PPCI and door-to-procedure completion time and
baseline platelet reactivity before PPCI.
Methods
Study design and duration
The PINPOINT-PPCI (A study of platelet inhibition,
using a ‘point of care’ platelet function test, following
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vation myocardial infarction) study is a single centre,
prospective, observational study. For each patient, the
study follow-up period is 30 days. The study is antici-
pated to last 24 months, including a 6 month run-in
period for catheter laboratory staff training on the multi-
plate analyser. Enrolment to the trial commenced in
June 2011.
Selection criteria
Patients presenting to the BHI, a regional heart attack
centre, are considered for inclusion in the study. Eligibil-
ity for the trial requires presentation with an acute
STEMI with planned treatment by PPCI. Participants
are excluded if there is evidence of active bleeding or
bleeding diathesis, previous history of cerebrovascular
event, weight <60 kg, use of clopidogrel, prasugrel or
ticagrelor within 7 days of presentation, or haemo-
dynamic instability.
Recruitment
Patients are identified on arrival at the BHI when pre-
senting with STEMI. The operator (interventional cardi-
ologist) explains the PINPOINT-PPCI study to eligible
patients and obtains verbal assent at the time of proced-
ural consent. Formal written study consent is obtained
within 24 hours of recruitment, following a period of re-
covery from the PPCI procedure and after a minimum
of 4 hours to review/discuss the details of the study, as
described in a patient information sheet (PIS).
Patients receive a 60 mg loading dose of prasugrel as
soon as possible on arrival to the hospital (emergency
room or cathlab). A loading dose of 300 mg of Aspirin is
either administered in the community or on arrival to
hospital. Bivalirudin is commenced at the start of the
PCI (0.75 mg/kg bolus followed by 1.75 mg/kg/h infu-
sion during the PCI). Use of unfractionated heparin is
discouraged and patients are excluded if requiring use of
a GPI or continuation of the bivalirudin infusion post-
procedure.
Study measurements
The primary outcome measure for the study is the ADP
receptor platelet function assessment measured in per-
ipheral ‘whole’ blood using a multiple electrode analyser
(MEA – Multiplate platelet function analysis). Secondary
outcome measures of platelet function include assess-
ment of the arachidonic acid pathway, thromboxane re-
ceptor and thrombin related platelet activation.
Platelet function (measured in peripheral ‘whole’ blood,
see above) will be assessed on arrival at hospital, immedi-
ately after completion of the PPCI and 1, 2 and 24 hours
after the completion of the procedure (Figure 1). Multiple
measurements will facilitate the generation of a profile ofplatelet function from presentation through the post-
procedural period, describing the combined waning effect
of bivalirudin and increasing platelet inhibition by prasu-
grel. These same platelet function measurements will en-
able assessment of the impact of initial platelet reactivity
and the door-to-procedure completion time on effective
platelet inhibition, as measured by ADP receptor platelet
function.
Additional secondary outcome measures include the in-
cidence of adverse clinical events at 24 hours and 30 days,
including major adverse cardiac events (MACE – a com-
posite of target vessel revascularisation, target lesion
revascularisation, non-fatal myocardial infarction, and car-
diac death), bleeding complications (using the trials in
myocardial infarction (TIMI) major and minor bleeding
criteria [8] and bleeding academic research consortium
(BARC) definition for bleeding [9]), and stent thrombosis
(Academic research consortium (ARC) definition [10]).
Confounding variables
We are measuring and recording variables that may po-
tentially confound the associations of interest. These
variables are: timing of symptoms/presentation relative
to initiation of treatment, age, co-existent diabetes, and
prior treatment with aspirin. All of these variables affect
the characteristics of the index MI and may also influ-
ence door-to-balloon time and platelet reactivity on
presentation.
Procedure/Laboratory methods
Platelet function is assessed at baseline and multiple
time points after completion of the PPCI procedure, i.e.
0, 1, 2 and 24 hours. Multiplate platelet function analysis
has been well validated for assessment of the anti-
platelet effect of ADP receptor inhibitors and aspirin, of-
fering very useful information regarding the future risk
of significant adverse events [11].
MEA-derived platelet function is assessed using ‘whole
blood’ samples. However, platelets are very sensitive to
mechanical disruption and have a tendency to aggregate
with time after obtaining the blood sample, impairing as-
sessment. Consequently, platelet function testing re-
quires careful sampling and timely analysis. MEA is a
‘point of care’ system and, therefore, we have installed a
multiplate platelet function analyser in the catheter la-
boratory, enabling us to undertake immediate analysis of
blood samples.
The MEA test requires a single 3 ml blood sample. At
baseline, the sample is withdrawn from the arterial
sheath (1 x 3 ml Hirudin sample) at the time of routine
blood sampling, before starting the PPCI. The second
sample (Time 1) is also taken from the arterial sheath at
the end of the procedure. Subsequent samples (Times
2–4) are taken 1, 2 & 24 hours following completion of
STEMI BHI Catheter Lab for PPCI
Bivalirudin 
Prasugrel 60mg
bolus 
Prasugrel 10mg daily 
24hours
& 30day
Multiplate Platelet Function Assessment
TIME 0 TIME 1
Immediate 
TIME 2
1hours 
TIME 3
2hours 
TIME 4
24hours 
Figure 1 Study schema.
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Where ever possible venepuncture is scheduled to co-
incide with clinically required phlebotomy. Platelet activ-
ity (arachidonic acid, thrombin receptor, thromboxane
receptor & ADP-receptor activation assessment – ASPI,
TRAP, U46119 & ADP tests) in the samples is assessed
immediately using the multiplate analyser.
Adverse event monitoring
Serious and other adverse events are recorded and re-
ported in accordance with the International Conference
for Harmonisation of Good Clinical Practice (ICH GCP)
guidelines and the Sponsor’s Research Related Adverse
Event Reporting Policy. However, the only research pro-
cedures that patients are required to undergo for this
study are venepuncture (for blood samples).
Sample size calculation
The primary analysis will be a mixed model regression
(see below) to test whether or not door-to-procedure
completion time and platelet function on arrival at hos-
pital are significant predictors of platelet function after
PPCI (key predictors of interest). In a multiple regres-
sion model, the analogous quantity to a “target differ-
ence” (for a binary predictor) is the target increase in the
proportion of the variance explained. In PINPOINT, this
target [that the study was powered to detect] was a 5%
increase in the proportion of the variance explained by
the model with and without the predictors of interest
(i.e. 25% for the full model, and 20% for the model ex-
cluding the key predictors of interest).
Two key predictors will be tested. Therefore, a signifi-
cance level of 0.025 will be adopted (Bonferroni correc-
tion) giving a nominal hypothesis test at p < 0.05 for each
predictor. For 80% power, the above assumptions require
a target sample size of 135. This target sample size needs
to be further adjusted by the relative efficiency of theanalysis, i.e. to take into account the three repeated mea-
sures. Estimating the relative efficiency requires further as-
sumptions about the correlations between the repeated
measures; for correlations ranging from 0.5 to 0.8, the
relative efficiency varies from 1.25 to 1.50. Taking the
lower estimate of relative efficiency gives a final target
sample size of 108 (i.e. 135/1.25).Statistical analysis
The primary analysis will be a mixed model regression
to take into account the four repeated measures of plate-
let function at the end of the procedure, 1, 2 and
24 hours after completion of PPCI. The analyses will ad-
just for the potential confounding factors described
above. The two key predictors will be tested in the final
model, namely the effects of (a) door-to-procedure com-
pletion time and (b) platelet function on arrival at the
hospital.
Secondary outcomes will be analysed using logistic re-
gression, adjusting separately for each of the key predic-
tors. Other potential confounding factors will only be
adjusted for in models if there have been sufficient num-
bers of outcome events that estimates can be estimated
reliably, i.e. over-adjustment is not considered to be a
potential problem.
The numbers of adverse events (both serious and non-
serious) will be described.Ethics
Ethics review of the protocol for the study and other
study-related essential documents (e.g. PIS, consent
form) was undertaken by a UK NHS Research Ethics
Committee (REC). This study does not raise any sub-
stantive ethical issues since participants are receiving
standard NHS care and are having a research procedure
that carries very little risk.
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European Union Directive 2001/20/EC on clinical trials,
the Medicine for Human Use (Clinical Trial) Regulations
2004, the International Conference for Harmonisation of
Good Clinical Practice (ICH GCP) guidelines and the
Research Governance Framework for Health and Social
Care.
Study limitations
The initial study design had anticipated a ‘run-in’ period
of catheter laboratory staff training and subsequent re-
cruitment of patients at any time during the day or night
during the working week. However, the Multiplate plate-
let function analyser is not a true ‘point of care’ test,
since it requires operators to be trained and takes ap-
proximately 10 minutes to process a sample. The mul-
tiple measurements required for each patient in the
study has precluded involvement of the staff in the cath-
eter laboratory and, instead, we are relying on dedicated
laboratory staff. The unpredictable nature of patients
presenting with STEMI combined with a need for
trained personnel to undertake the test has limited re-
cruitment to periods when laboratory staff are available;
this has mainly restricted enrolment to Monday-Friday,
0800–1600 hours. Furthermore, the time constraints as-
sociated with multiple measures of platelet function re-
sulted in rationalisation of the study protocol, which
initially included a 4 hour post-procedure timepoint. Al-
though, additional timepoints would provide more infor-
mation regarding the kinetic of platelet inhibition, it was
felt that the logistical implications would jeopardise
recruitment to the study. Patients with thrombotic compli-
cations during PPCI, requiring ongoing intravenous anti-
thrombotic/anti-platelet therapy (physician discretion),
are excluded from the trial due to the impact that ongoing
intravenous therapy has on the platelet function assess-
ment. This group of patients merit further investigation.
The emergency nature of presentation with STEMI
prevents a standard consenting process for participation
in clinical trials. Verbal assent with written consent de-
layed until after acute treatment is an accepted method
of recruitment in the emergency setting and has been
successfully adopted in our department for a number of
trials. Both staff and patients accept the process and to
date, all patients assenting to the study have subse-
quently completed written consent.
Discussion
This study is assessing the acute variability of platelet re-
activity at the time of presentation with STEMI and the
impact of accelerated ‘door-to-balloon’ time on the
platelet inhibitory effect of anti-thrombotic and anti-
platelet agents within the first 24 hours of care. Debate
continues regarding the acute safety of bivalirudinmonotherapy in the treatment of STEMI [12-14]. Des-
pite evidence of rapid platelet inhibition with prasugrel
in stable patients, and encouraging early reports of their
combined use [15], it is not clear if the combination of
prasugrel and bivalirudin is sufficient to prevent acute
stent thrombosis. It is possible that the baseline platelet
reactivity, on presentation with a STEMI, impacts on the
effect of acute anti-thrombotic and anti-platelet therapy
and exposes patients to a risk of bleeding or ongoing
thrombosis. We anticipate that demonstration of the
baseline variation in platelet reactivity in patients experi-
encing acute STEMI and definition of the pharmacody-
namic response to combined treatment with bivalirudin
and prasugrel will facilitate optimisation of pharmaco-
therapeutic strategies utilised in the acute phase of treat-
ment for STEMI.
Trial status
Recruitment to the PINPOINT study is nearing comple-
tion, with 100patients recruited. It is anticipated that the
study results will be available for dissemination later in
2013.
Abbreviations
STEMI: ST elevation myocardial infarction; PCI: Percutaneous coronary
intervention; PPCI: Primary percutaneous coronary intervention; BHI: Bristol
Heart Institute; UFH: Unfractionated heparin; GPI: Glycoprotein 2b/3a
inhibitor; MACE: Major adverse cardiovascular events; ADP: Adenosine
di-phosphate; MEA: Multiple electrode analyser; TIMI: Trials in myocardial
infarction; ARC: Academic research consortium.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
TJ conceived the study, AM, SM, MB, BR, AB & TJ participated in the design
of the study, and writing of the protocol. TJ, DM, AM, KP, RB, JWS, BR, CR &
AB contributed to the writing of the manuscript and all authors have read
and approved the final manuscript.
Acknowledgements
The study has been funded by the Above & Beyond Charitable Trust, The
Medicine’s Company and the UK National Institute for Health Research
(NIHR) Bristol Cardiovascular Biomedical Research Unit. This paper presents
independent research. The views expressed are those of the authors and not
necessarily those of the NHS, the NIHR or the UK Department of Health.
Author details
1Bristol Heart Institute, Bristol Royal Infirmary, Upper Maudlin Street, Bristol
BS2 8HW, UK. 2University of Bristol, Bristol Royal Infirmary, Upper Maudlin
Street, Bristol BS2 8HW, UK.
Received: 29 June 2013 Accepted: 31 March 2014
Published: 4 April 2014
References
1. Keeley EC, Boura JA, Grines CL: Comparison of primary and facilitated
percutaneous coronary interventions for ST-elevation myocardial
infarction: quantitative review of randomised trials. Lancet 2006,
367(9510):579–588.
2. Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR,
Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Wong SC, Nikolsky
E, Gambone L, Vandertie L, Parise H, Dangas GD, Stone GW: Bivalirudin in
patients undergoing primary angioplasty for acute myocardial infarction
Johnson et al. BMC Cardiovascular Disorders 2014, 14:44 Page 6 of 6
http://www.biomedcentral.com/1471-2261/14/44(HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet
2009, 374(9696):1149–1159.
3. Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe
CH, Antman EM: Prasugrel compared with clopidogrel in patients
undergoing percutaneous coronary intervention for ST-elevation
myocardial infarction (TRITON-TIMI 38): double-blind, randomised
controlled trial. Lancet 2009, 373(9665):723–731.
4. Wallentin L, Varenhorst C, James S, Erlinge D, Braun OÃ, Jakubowski JA,
Sugidachi A, Winters KJ, Siegbahn A: Prasugrel achieves greater and faster
P2Y12receptor-mediated platelet inhibition than clopidogrel due to
more efficient generation of its active metabolite in aspirin-treated
patients with coronary artery disease. Eur Heart J 2008, 29(1):21–30.
5. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D,
Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane
AJ, Parise H, Mehran R and the HORIZONS-AMI Trial Investigators:
Bivalirudin during primary PCI in acute myocardial infarction.
N Engl J Med 2008, 358(21):2218–2230.
6. Parodi G, Valenti R, Bellandi B, Migliorini A, Marcucci R, Comito V, Carrabba
N, Santini A, Gensini GF, Abbate R, Antoniucci D: Comparison of prasugrel
and ticagrelor loading doses in ST-segment elevation myocardial
infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs)
primary PCI study. J Am Coll Cardiol 2013, 61(15):1601–1606.
7. Valgimigli M, Tebaldi M, Campo G, Gambetti S, Bristot L, Monti M, Parrinello
G, Ferrari R: Prasugrel versus tirofiban bolus with or without short
post-bolus infusion with or without concomitant prasugrel
administration in patients with myocardial infarction undergoing
coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By
drOpping or shortening Infusion Line in patients with ST-segment
elevation myocardial infarction compared to or on top of PRasugrel
given at loading dOse) trial. JACC Cardiovasc Interv 2012, 5(3):268–277.
8. Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, Bell WR, Knatterud
G, Robertson TL, Terrin ML: Thrombolysis in Myocardial Infarction (TIMI)
Trial - Phase 1: Haemorrhagic Manifestations and changes in plasma
fibrinogen and the fibrinolytic system in patients treated with
recombinant tissue plasminogen activator and streptokinase. JACC 1988,
11(1):1–11.
9. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S,
Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P,
Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H:
Standardized bleeding definitions for cardiovascular clinical trials.
Circulation 2011, 123(23):2736–2747.
10. Mauri L, Hsieh W-h, Massaro JM, Ho KKL, D'Agostino R, Cutlip DE: Stent
thrombosis in randomized clinical trials of drug-eluting stents.
N Engl J Med 2007, 356(10):1020–1029.
11. Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schömig A, Kastrati A, von
Beckerath N: Platelet reactivity after clopidogrel treatment assessed with
point-of-care analysis and early drug-eluting stent thrombosis.
J Am Coll Cardiol 2009, 53(10):849–856.
12. Dangas GD, Mehran R, Nikolsky E, Claessen BE, Lansky AJ, Brodie BR,
Witzenbichler B, Guagliumi G, Peruga JZ, Dudek D, M√∂ckel M, Caixeta A,
Parise H, White H, Stone GW: Effect of switching antithrombin agents for
primary angioplasty in acute myocardial infarction: the
HORIZONS-SWITCH analysis. J Am Coll Cardiol 2011, 57(23):2309–2316.
13. Langrish JP, Fox KAA: Optimal antithrombotic treatment during primary
percutaneous coronary intervention? Heart 2011, 97(18):1459–1460.
14. Koutouzis M, Lagerqvist B, James S, Omerovic E, Matejka G, Grip L,
Albertsson P: Unfractionated heparin administration in patients treated
with bivalirudin during primary percutaneous coronary intervention is
associated lower mortality and target lesion thrombosis: a report from
the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
Heart 2011, 97(18):1484–1488.
15. Baumbach A, J T, Oriolo V, Kesavan S, Davis A, Smith D, Edmond J, Reeves
BC, Strange JW: Prasugrel and bivalirudin for primary angioplasty: early
results on stent thrombosis and bleeding. Int J Cardiol 2011, 153(2):222–224.
doi:10.1186/1471-2261-14-44
Cite this article as: Johnson et al.: Point of care platelet activity
measurement in primary PCI [PINPOINT-PPCI]: a protocol paper.
BMC Cardiovascular Disorders 2014 14:44.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
